DiscoverThe Morning BriefDiabetes Drugs: Bittersweet Truth of Patent Expiries
Diabetes Drugs: Bittersweet Truth of Patent Expiries

Diabetes Drugs: Bittersweet Truth of Patent Expiries

Update: 2022-07-25
Share

Description

With the oral diabetes drugs market at Rs 13,000 crore and growing, a key diabetes medicine Sitagliptin going off patent means a sweet spot for all. How does the billion-dollar pharma industry see an opportunity in a market with the highest number of diabetes patients in the world. Host Kiran Somvanshi chats with Nithya Balasubramanian, Director at AB Bernstein, Sheetal Sapale, Marketing President - AWACS, and Vikas Dandekar, Editor - Pharma at ET Prime.

Credits: CNBC-TV18

See omnystudio.com/listener for privacy information.

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Diabetes Drugs: Bittersweet Truth of Patent Expiries

Diabetes Drugs: Bittersweet Truth of Patent Expiries

The Economic Times